Physician samples valuation falls under Section 4(1)(a) not cost construction method under Section 4(1)(b) CESTAT Ahmedabad held that valuation of physician samples falls under Section 4(1)(a) rather than cost construction method under Section 4(1)(b). The ...
Cases where this provision is explicitly mentioned in the judgment/order text; may not be exhaustive. To view the complete list of cases mentioning this section, Click here.
Provisions expressly mentioned in the judgment/order text.
Physician samples valuation falls under Section 4(1)(a) not cost construction method under Section 4(1)(b)
CESTAT Ahmedabad held that valuation of physician samples falls under Section 4(1)(a) rather than cost construction method under Section 4(1)(b). The Tribunal found the issue was res-integra, having been previously decided in appellant's favor in multiple orders. Since price was charged from distributors, the case was covered under Section 4(1)(a) provisions, making Central Excise Rules inapplicable. Following established precedent, the demand was deemed unsustainable and impugned orders were set-aside, allowing the appeal.
Issues: Valuation of physician samples under Section 4(1)(a) or cost construction method proportionate to MRP in terms of Section 4(1)(b).
Analysis: The judgment of the Appellate Tribunal CESTAT Ahmedabad, delivered by Hon'ble Mr. Ramesh Nair and Hon'ble Mr. C. L. Mahar, addressed the issue of valuation of physician samples under Section 4(1)(a) or Section 4(1)(b) of the Central Excise Act. The appellant's counsel, Ms. Nidhi Nawal, argued that the issue had been previously decided in the appellant's favor by the Tribunal and affirmed by the Hon'ble Supreme Court in a related case involving Sun Pharmaceutical Industries Ltd. The Revenue, represented by Shri Anoop Kumar Mudvel, reiterated the findings of the impugned order.
Upon careful consideration, the Tribunal found that the issue was no longer res-integra as it had been conclusively settled in the appellant's case through various orders of the Tribunal. One such order, dated 12.09.2023, highlighted that physician samples, not meant for sale but for free distribution to physicians, should be valued under Section 4, where excise duty is payable on the transaction value. The Tribunal referred to Section 4(1)(a) of the Act, emphasizing that the transaction value between the assessee and distributor should be considered for valuation, irrespective of the final recipients of the samples.
The Tribunal rejected the Revenue's contention that since the physician samples were given free of cost to physicians by distributors, the case did not fall under Section 4(1)(a). It clarified that the crucial transaction occurred between the assessee and distributors, where a price was charged, making Section 4(1)(a) applicable. The Tribunal held that the decision rendered by the CESTAT correctly interpreted the law, dismissing the Revenue's appeals based on the incorrect premise that the samples were not sold by the distributors to physicians.
Ultimately, the Tribunal concluded that the issue had been definitively settled in favor of the appellant based on previous orders and the Supreme Court judgment. Consequently, the impugned orders were set aside, and the appeals were allowed, affirming the valuation of physician samples under Section 4(1)(a) and rejecting the Revenue's arguments.
Full Summary is available for active users!
Note: It is a system-generated summary and is for quick reference only.